<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095366</url>
  </required_header>
  <id_info>
    <org_study_id>ALGOFINE-2</org_study_id>
    <nct_id>NCT02095366</nct_id>
  </id_info>
  <brief_title>Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting</brief_title>
  <acronym>ALGOFINE-2</acronym>
  <official_title>Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting. A Multicenter,Randomized,Controled, Comparative, Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Apicil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SFMU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal (IN) administration of opiates is an appealing non-invasive way of treating acute
      traumatic pain in prehospital and Emergency departments (ED).

      The investigators hypothesize that IN administration of Sufentanil is equal as compared with
      Intra veinous (IV) administration of Morphine wich is widely recommended in ED.

      The investigators study is a multicentric, comparative, randomized, double-blind,
      double-placebo study, comparing quality of analgesia in both groups 30 minutes after first
      administration of opiates.

      The investigators also asses side effects and patient satisfaction in both groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2013</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 10, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficiency of Analgesia</measure>
    <time_frame>30 minutes</time_frame>
    <description>Patient self-assessed pain intensity using Numeric Pain Rating Scale (0 to 10). 30 minutes after the first opiate administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid-related side effects</measure>
    <time_frame>10 minutes</time_frame>
    <description>Sedation Score, Breathing Rate, Oxygen Saturation, Arterial Blood Pressure, Heart rate, Nasal Ulceration.
Proportion of patients having opioid-related side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency of Analgesia</measure>
    <time_frame>Every 10 minutes</time_frame>
    <description>Patient self-assessed pain intensity using Numeric Pain Rating Scale (0 to 10). 10 minutes and 20 minutes after the first opiate administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>40 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Analysis for the pre hospital setting group: Efficiency of Analgesia</measure>
    <time_frame>Every 10 minutes</time_frame>
    <description>Patient self-assessed pain intensity, using Numeric Pain Rating Scale (0 to 10) at 10, 20 and 30 min after the first opiate administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Severe Traumatic Pain</condition>
  <condition>Numeric Pain Rating Scale &gt; 5 / 10</condition>
  <arm_group>
    <arm_group_label>IN Sufentanil AND IV Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Morphine AND IN Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS&gt;3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS&gt;3: Pacebo (1 spray) + morphine IV 0,05mg/kg</description>
    <arm_group_label>IV Morphine AND IN Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS&gt;3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS&gt;3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV</description>
    <arm_group_label>IN Sufentanil AND IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS&gt;3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS&gt;3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV</description>
    <arm_group_label>IN Sufentanil AND IV Placebo</arm_group_label>
    <other_name>saline solution</other_name>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS&gt;3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS&gt;3: Pacebo (1 spray) + morphine IV 0,05mg/kg</description>
    <arm_group_label>IV Morphine AND IN Placebo</arm_group_label>
    <other_name>saline solution</other_name>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic pain

          -  Numeric Pain Rating Scale (NPRS) &gt;5 /10

          -  Age between 18 and 75 years old

        Exclusion Criteria:

          -  Medical pain (headache, chest pain,...)

          -  Respiratory, renal or hepatic insufficiency

          -  Drug addiction

          -  Medical or Chirurgical sinus history

          -  Oxygene saturation &lt; 90%

          -  Systolic blood pressure &lt; 90mmHg

          -  Head injury with a neurological Glasgow Coma Scale (GCS) &lt; 14

          -  Opioid allergy

          -  Facial traumatism

          -  Patient unable do understand or assessing NPRS

          -  Opiates administration within 6 hours before admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emergency Department - Hospital Albertville</name>
      <address>
        <city>Albertville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department - Hospital Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department - Hospital Chambéry</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department - University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department - Hospital Saint Jean de Maurienne</name>
      <address>
        <city>Saint-Jean-de-Maurienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Department - Hospital Voiron</name>
      <address>
        <city>Voiron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Grenoble</investigator_affiliation>
    <investigator_full_name>AdministrateurDRC</investigator_full_name>
    <investigator_title>Delegation de la recherche clinique et de l'innovation</investigator_title>
  </responsible_party>
  <keyword>Acute Pain</keyword>
  <keyword>Traumatic Pain</keyword>
  <keyword>Emergency setting</keyword>
  <keyword>Prehospital setting</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Intranasal device</keyword>
  <keyword>Intra veinous injection</keyword>
  <keyword>Sufentanil citrate</keyword>
  <keyword>Morphine Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

